Eurasian Patent No. 034390 protected the use of a combination of the known antibodies pertuzumab and trastuzumab in combination with chemotherapy containing docetaxel and carboplatin for the neoadjuvant treatment of HER2-positive early-stage breast cancer. Previously, the panel of Chamber for Patent Disputes upheld the opposition filed by «A.Zalesov & Partners» Patent & Law Firm team and invalidated Eurasian Patent No. 034390 in full on the territory of the Russian Federation. This decision was not upheld, and the case was sent back for reconsideration.
Following the retrial, on January 31, 2026, EA patent No. 034390 was invalidated again. «A.Zalesov & Partners» team, including Partner and Head of the Patent Department Maria Makhlina and Head of the medical and pharmaceutical patent group Julia Dutikova, played a key role in challenging the patent at this stage.
The successful reconsideration of EA patent No. 034390 demonstrates the strength of the legal position. The combination of patent and industry expertise enabled the firm to convincingly justify the non-compliance of the decision regarding the disputed patent with legal requirements and achieve the final invalidation of the patent.